A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Head and Neck Squamous Cell Carcinoma|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Carcinoma|Glioblastoma Multiforme
Interventions: DRUG: ABBV-221
Sponsor: AbbVie